136 related articles for article (PubMed ID: 11849778)
1. PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification.
Muracciole X; Romain S; Dufour H; Palmari J; Chinot O; Ouafik L; Grisoli F; Branger DF; Martin PM
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):592-8. PubMed ID: 11849778
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
3. Ki-67: a prognostic factor for low-grade glioma?
Fisher BJ; Naumova E; Leighton CC; Naumov GN; Kerklviet N; Fortin D; Macdonald DR; Cairncross JG; Bauman GS; Stitt L
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):996-1001. PubMed ID: 11958894
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of prognostic factors for survival in
elderly patients with glioma].
Liu J; Lou M; Ji P; Li C; Feng F; Li B; Xu M; Gao G; Qu Y; Wang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 43(4):403-409. PubMed ID: 29774877
[TBL] [Abstract][Full Text] [Related]
5. Putamen involvement and survival outcomes in patients with insular low-grade gliomas.
Wang Y; Wang Y; Fan X; Li S; Liu X; Wang J; Jiang T
J Neurosurg; 2017 Jun; 126(6):1788-1794. PubMed ID: 27564467
[TBL] [Abstract][Full Text] [Related]
6. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
[TBL] [Abstract][Full Text] [Related]
7. High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas.
Iwadate Y; Hayama M; Adachi A; Matsutani T; Nagai Y; Hiwasa T; Saeki N
Anticancer Res; 2008; 28(1B):415-8. PubMed ID: 18383878
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Caccamo DV; Keohane ME; McKeever PE
Mod Pathol; 1994 Jan; 7(1):99-104. PubMed ID: 8159659
[TBL] [Abstract][Full Text] [Related]
9. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
10. Co-expression of midkine and pleiotrophin predicts poor survival in human glioma.
Ma J; Lang B; Wang X; Wang L; Dong Y; Hu H
J Clin Neurosci; 2014 Nov; 21(11):1885-90. PubMed ID: 25001988
[TBL] [Abstract][Full Text] [Related]
11. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 expression in higher-grade human glioma: a clinical and experimental study.
Fels C; Schäfer C; Hüppe B; Bahn H; Heidecke V; Kramm CM; Lautenschläger C; Rainov NG
J Neurooncol; 2000 Jul; 48(3):207-16. PubMed ID: 11100818
[TBL] [Abstract][Full Text] [Related]
15. Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma.
Salmaggi A; Croci D; Prina P; Cajola L; Pollo B; Marras CE; Ciusani E; Silvani A; Boiardi A; Sciacca FL
Cancer Biol Ther; 2006 Feb; 5(2):204-9. PubMed ID: 16357523
[TBL] [Abstract][Full Text] [Related]
16. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
J Clin Oncol; 1999 Oct; 17(10):3048-57. PubMed ID: 10506599
[TBL] [Abstract][Full Text] [Related]
17. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
18. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
19. FGF2 as a potential prognostic biomarker for proneural glioma patients.
Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist PH; Pontén F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S
Acta Oncol; 2015 Mar; 54(3):385-94. PubMed ID: 25263081
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
